Deepak L. Bhatt,
Ragavendra R. Baliga
Elsevier Health Sciences
e druk, 2022
9780323960465
SGLT-2 Inhibitors, An Issue of Heart Failure Clinics
Specificaties
Gebonden, blz.
|
Engels
Elsevier Health Sciences |
2022
ISBN13: 9780323960465
Rubricering
Onderdeel van serie
The Clinics: Internal Medicine
Levertijd ongeveer 9 werkdagen
Gratis verzonden
Samenvatting
In this issue, guest editors bring their considerable expertise to this important topic.
Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.
Specificaties
Inhoudsopgave
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors<br>Renoprotective Effects of SGLT2 Inhibitors<br>SGLT2 Inhibitors in Type 2 Diabetes Mellitus<br>SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection<br>SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction<br>SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits<br>Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events<br>SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature<br>Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease<br>SGLT2 Inhibitors and Safety in Older Patients<br>Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk